THY1 and cancer: Several of the most often used cancer stem cell markers in the recruited studies, including ICAM-1 [35], CD133 [36,38], CD90 [34,36,38], CD44 [34,37], CK19 [36], and Nanog [31], were evaluated to determine whether CCSCs may possibly be employed for HCC prognostic prediction.